AAPP supports access to antidepressants for youth with moderate to severe symptoms of a depressive, anxiety, or obsessive-compulsive-based disorder and reconsideration of the boxed warning on new-onset suicidal thoughts/behaviors given its many unintended consequences and role in accelerating stigma. Psychiatric pharmacists are encouraged to use this policy brief to support your own advocacy for this gold-standard treatment.